Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer

NCT00144378 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT00144378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study With Irinotecan+Best Supportive Care Versus Only Best Supportive Care as Second Line Therapy for Metastatic Gastric Cancer
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2002
Completion date
Not reported
Enrollment
44
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, stomach neoplasm